IXC Stock Overview
A biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
Invex Therapeutics Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.084 |
| 52 Week High | AU$0.26 |
| 52 Week Low | AU$0.061 |
| Beta | 0.41 |
| 11 Month Change | 6.33% |
| 3 Month Change | n/a |
| 1 Year Change | -64.26% |
| 33 Year Change | -88.00% |
| 5 Year Change | -88.00% |
| Change since IPO | -91.60% |
Recent News & Updates
Recent updates
Shareholder Returns
| IXC | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | 0% | 4.4% | 0.7% |
| 1Y | -64.3% | 63.3% | 16.7% |
Return vs Industry: IXC underperformed the Australian Pharmaceuticals industry which returned 63.3% over the past year.
Return vs Market: IXC underperformed the Australian Market which returned 16.7% over the past year.
Price Volatility
| IXC volatility | |
|---|---|
| IXC Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 11.5% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in AU Market | 17.2% |
| 10% least volatile stocks in AU Market | 3.5% |
Stable Share Price: IXC's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: Insufficient data to determine IXC's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2019 | n/a | n/a | www.invextherapeutics.com |
Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase III clinical trial. The company was incorporated in 2019 and is based in Perth, Australia.
Invex Therapeutics Ltd Fundamentals Summary
| IXC fundamental statistics | |
|---|---|
| Market cap | AU$6.76m |
| Earnings (TTM) | -AU$1.64m |
| Revenue (TTM) | AU$1.21m |
5.6x
P/S Ratio-4.1x
P/E RatioIs IXC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IXC income statement (TTM) | |
|---|---|
| Revenue | AU$1.21m |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$1.21m |
| Other Expenses | AU$2.85m |
| Earnings | -AU$1.64m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.022 |
| Gross Margin | 100.00% |
| Net Profit Margin | -135.43% |
| Debt/Equity Ratio | 0% |
How did IXC perform over the long term?
See historical performance and comparison